



Empirical evidence showing wider impact of immunisation



Gender

Measles vaccination benefits girls more



Poverty

30-40% of deaths averted by PCV / pneumonia treatment occur in the **poorest wealth quintile** (Ethiopia study)



Malnutrition

Immunisation **reduces** the proportion of **children with stunting by 27%** (Kenya study)




Education

One additional grade of schooling achieved for every 6 children vaccinated in poor, rural settings (South Africa study)




Continued progress on routine introductions and uptake




Note: Introductions in 68 Gavi-eligible countries (except for regional vaccines – Yellow Fever, Japanese Encephalitis and Meningitis A where target countries are a subset of eligible countries) – introductions exclude certain product switches during Gavi 1.0 and 2.0 period

Campaigns are a substantial part of Gavi efforts

Number of routine introductions vs campaigns 2016-2019* (forecast)






- Measles outbreak Sept. 2018 May 2019:
 >145,000 cases and >900 deaths
- Regular campaigns did not prevent outbreak

A closer look at Pakistan's recent measles campaign



Measles post-campaign survey coverage (%) by region





 Over 37 million children vaccinated,
 10% zero-dose



 93% coverage across provinces



0.63% refusal



 No serious adverse events

- Stepped up advocacy, communication & social mobilisation
- Detailed data-driven microplanning
- Strong collaboration with polio eradication staff
- PEF TCA: US\$ 3m to core partners for 27 on-ground staff











Effective Vaccine Management (EVM) scores are improving

Composite EVM scores



EVM improvements in areas where Gavi has invested


Average EVM scores per criteria from previous & latest assessments






Gavi's model driving higher allocation of domestic resources for immunisation

Countries' co-financing & self-financing in US\$ millions




Ripple effect beyond Gavi-supported vaccines

Domestic and donor funding for non-Gavi supported vaccines





Progress on price reduction and product innovation; continued risks on supply



Continued Alliance efforts to mitigate global supply shortage for Rotavirus, HPV and IPV





Supply in 2019 & 2020 lower than expected



- Alliance collaboration to mitigate impact of shortage
- 2 new manufacturers in 2018 and 1 new presentation in 2019



- Improvements: supply secured for routine programmes
- Supply & pricing expected to improve with new entrants

